Christel C. Bastida

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

Gerald S. Falchook, Jonathan C. Trent, Michael C. Heinrich et al. · Oncotarget · 2013 · 166 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer

Gerald S. Falchook, Nelson G. Ordóǹez, Christel C. Bastida et al. · Journal of Clinical Oncology · 2014 · 70 citations

Medicine, Oncology, Pharmacology +12

Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatment

Gerald S. Falchook, Scott M. Lippman, Christel C. Bastida et al. · Head & Neck · 2013 · 52 citations

Medicine, Oncology, Chemotherapy +15

Functional networks underlying latent inhibition learning in the mouse brain

Frank Puga, Douglas W. Barrett, Christel C. Bastida et al. · NeuroImage · 2007 · 40 citations · Full text

Life Sciences, Neurobiology, Neuroscience +16

Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale

Tito R. Mendoza, Xin Shelley Wang, Loretta A. Williams et al. · Journal of Pain · 2015 · 36 citations

Medicine, Neurology, Neuroscience +10